Prothena Corporation plc (PRTA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Gene G. Kinney Ph.D. | President, CEO & Director | 1.06M | -- | 1969 |
| Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer | 885.65k | -- | 1974 |
| Mr. Brandon S. Smith | Chief Operating Officer | 796.01k | -- | 1975 |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer | 704.33k | -- | 1973 |
| Ms. Carol D. Karp | Chief Regulatory Officer | 735.55k | -- | 1953 |
| Ms. Karin L. Walker CPA | Chief Accounting Officer & Controller | -- | -- | 1963 |
| Mr. Mark C. Johnson C.F.A. | Vice President of Investor Relations | -- | -- | -- |
| Mr. Michael J. Malecek | Chief Legal Officer & Company Secretary | 588.25k | -- | 1966 |
| Mr. David A. Ford | Chief People Officer | -- | -- | 1970 |
| Dr. Chad J. Swanson Ph.D. | Chief Development Officer | -- | -- | -- |
Prothena Corporation plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 163
Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Corporate Governance
Upcoming Events
May 8, 2025 at 8:00 PM UTC
Prothena Corporation plc Earnings Date